Clinical and pathologic characteristics of breast cancer patients carrying the c.3481_3491del11 mutation
- 115 Downloads
Tumor characteristics are used today to evaluate the possibility of mutation and to target mutation screening in families with high risk of breast and/or ovarian cancer. We studied the breast tumor profile associated to the c.3481_3491del11 French founder effect mutation on the BRCA1 gene to an attempt to identify any particularity or difference when comparing it to that related to other BRCA1 mutations. Within the population who were referred to our oncogenetic clinic at the Lorraine Oncology Institute in France and who underwent genetic testing between 1994 and 2012, we identified 404 women carrying a BRCA1 mutation. Interestingly, 45% (180/404) women had the germline c.3481_3491del11 mutation. These included 91 patients affected by first breast cancer. Clinical and pathologic data were retrieved from medical files. Descriptive statistics were conducted using the SPSS software (version 20.0). For the entire cohort of 91 women, the mean age was 43.64 years (SD 10.04). Tumors were identified in 37.4% of cases aged < 40 years. Estrogen receptor status and progesterone receptor status were reported to 67 patients. Seventy-four percent were ER negative. Hormonal receptors status was negative in 68.6% of tumors. HER2 status was available for 32 tumors. The triple-negative subtype was found in 21 cases, which accounts for 65.6% of the patients. High tumor grade was found in 81% of triple negative breast cancer patients. Based on our results compared to those of previous international studies, we concluded that the breast cancer associated to the c.3481_3491del11 is not different from that associated to other BRCA1 mutations. A larger cohort with complete information on the breast cancer pathologic characteristics and including other BRCA1 mutations would allow us to statistically compare the breast tumor profile associated to the c.3481_3491del11 to that related to other BRCA1 mutations.
KeywordsBRCA1 C.3481_3491del11 Breast cancer phenotype Pathologic characteristics Hormonal receptors
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
This project was performed in compliance with the relevant ethical standards in France.
- 1.Fricker JP, Muller D, Cutuli B, Rodier JF, Janser JC, Jung GM, Mors R, Petit T, Haegele P, Abecassis J (2000) Germ-line mutations at BRCA1 in northeastern France. Bull Cancer 87(10):739–744Google Scholar
- 6.Lahkani SR, van de Vijver MJ, Jacquemier J, Anderson TJ, Osin PP, McGuffog L et al (2002) The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 20:2310–2318CrossRefGoogle Scholar
- 14.Peyrat JP, Vennin P, Hornez L, Bonneterre J (1997) Mutations germinales de BRCA1 chez 36 patientes atteintes de cancer du sein et/ou de l’ovaire et appartenant à des familles à risque du Nord de la France. Bull Cancer 84(1):41–46Google Scholar
- 15.Eisinger F, Bressac B, Castaigne D, Cottu PH, Lansac J, Lefranc JP et al (2004) Identification et prise en charge des prédispositions héréditaires aux cancers du sein et de l’ovaire. Bull Cancer 91:219–237Google Scholar
- 17.Musolino A, Michiara M, Bella M, Naldi N, Zanelli P et al (2005) Molecular profile and clinical variables in BRCA1-positive breast cancers: a population-based study. Tumori 91:505–512Google Scholar
- 20.Vaziri S, Krumrey L, Elson P et al (2001) Breast tumor immunophenotype of BRCA1-mutation carriers is influenced by age at diagnosis. Clin Cancer Res 7:1937–1945Google Scholar
- 30.Thompson D, Easton D (2002) Breast Cancer Linkage Consortium. Variation in BRCA1 cancer risks by mutation position. Cancer Epidemiol Biomark Prev 11(4):329–336Google Scholar
- 31.Lecarpentier J, Noguès C, Mouret-Fourme E, Stoppa-lyonnet D, Lasset C et al (2012) Variation in breast cancer risk with mutation position, smoking, alcohol, and chest X-ray history, in the French National BRCA1/2 carrier cohort (GENEPSO). Breast Cancer Res Treat 14:1–13Google Scholar